Switch theme
Sign up to access all valuation multiples
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
2015
64
LTM Revenue $0.6M
LTM EBITDA -$68.7M
-$168M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioage Labs has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of -$68.7M.
In the most recent fiscal year, Bioage Labs achieved revenue of n/a and an EBITDA of -$68.6M.
Bioage Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioage Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$68.7M | XXX | -$68.6M | XXX | XXX | XXX |
| EBITDA Margin | -12294% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$75.9M | XXX | -$78.2M | XXX | XXX | XXX |
| EBIT Margin | -13591% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$69.8M | XXX | -$71.1M | XXX | XXX | XXX |
| Net Margin | -12494% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bioage Labs's stock price is $4.
Bioage Labs has current market cap of $142M, and EV of -$168M.
See Bioage Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$168M | $142M | XXX | XXX | XXX | XXX | $-4.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bioage Labs has market cap of $142M and EV of -$168M.
Bioage Labs's trades at n/a EV/Revenue multiple, and 2.4x EV/EBITDA.
Equity research analysts estimate Bioage Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioage Labs has a P/E ratio of -2.0x.
See valuation multiples for Bioage Labs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV (current) | -$168M | XXX | -$168M | XXX | XXX | XXX |
| EV/Revenue | -300.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 2.4x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBIT | 2.2x | XXX | 2.1x | XXX | XXX | XXX |
| EV/Gross Profit | -300.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioage Labs's last 12 month revenue growth is 42%
Bioage Labs's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Bioage Labs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioage Labs's rule of X is -12189% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioage Labs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -12294% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -12189% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioage Labs acquired XXX companies to date.
Last acquisition by Bioage Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioage Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bioage Labs founded? | Bioage Labs was founded in 2015. |
| Where is Bioage Labs headquartered? | Bioage Labs is headquartered in United States of America. |
| How many employees does Bioage Labs have? | As of today, Bioage Labs has 64 employees. |
| Who is the CEO of Bioage Labs? | Bioage Labs's CEO is Dr. Kristen Fortney, PhD. |
| Is Bioage Labs publicy listed? | Yes, Bioage Labs is a public company listed on NAS. |
| What is the stock symbol of Bioage Labs? | Bioage Labs trades under BIOA ticker. |
| When did Bioage Labs go public? | Bioage Labs went public in 2024. |
| Who are competitors of Bioage Labs? | Similar companies to Bioage Labs include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bioage Labs? | Bioage Labs's current market cap is $142M |
| What is the current revenue of Bioage Labs? | Bioage Labs's last 12 months revenue is $0.6M. |
| What is the current revenue growth of Bioage Labs? | Bioage Labs revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Bioage Labs? | Current revenue multiple of Bioage Labs is -300.5x. |
| Is Bioage Labs profitable? | Yes, Bioage Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioage Labs? | Bioage Labs's last 12 months EBITDA is -$68.7M. |
| What is Bioage Labs's EBITDA margin? | Bioage Labs's last 12 months EBITDA margin is -12294%. |
| What is the current EV/EBITDA multiple of Bioage Labs? | Current EBITDA multiple of Bioage Labs is 2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
